

P R E S S R E L E A S E

SHS invests in cardiology specialist Vimecon



Tübingen/Herzogenrath, December 16, 2014 – The fourth fund of the Tübingen based growth investor SHS Gesellschaft für Beteiligungsmanagement has invested in Vimecon GmbH together with existing and new investors. Founded in 2005, Vimecon develops and produces laser catheters to treat heart disease with a focus on atrial fibrillation. Existing investors include S-VC GmbH, NRW.Bank, KfW and private investors. New investors include DSA Invest GmbH and other private investors.

Atrial fibrillation is one of the most common heart diseases. It currently affects approximately one to two percent of the population and this is set to increase. About one million people are affected in Germany alone and around six million patients suffer from atrial fibrillation throughout Europe. When untreated, atrial fibrillation can result in strokes, congestive heart failure or thromboembolic complications.

"The market for atrial fibrillation treatment using catheter ablation is experiencing strong growth. With its innovative laser-based ablation procedure, Vimecon provides physicians with the possibility of treating their patients more effectively, safely and quickly so that even more patients can benefit from this treatment form in the future," explains Manfred Ulmer-Weber, SHS Senior Investment Manager. SHS partner Dr. André Zimmermann adds, "The innovative technological approach and the management team headed by company founder Dr. Kai Markus have convinced us that this is an excellent investment."

"We are happy to have found an investor like SHS with extensive experience in the medical technology sector. The fact that the existing investors have also increased their commitment attests to Vimecon's positive development," explains Vimecon's managing director and founder, Dr. Kai Markus.

About SHS Gesellschaft für Beteiligungsmanagement mbH:

SHS invests in life science and medical technology companies with high growth potential in the German speaking world. Its investment activities focus on growth financing, changes of ownership and successor situations. SHS has been active in the investment business for more than 20 years. Its principal partners are former McKinsey consultants Bernhard Schirmers and Reinhilde Spatscheck along with Hubertus Leonhardt, who previously served as Corporate Finance Project Manager at Arthur Andersen.

Investors have thus far provided over 100 million euros for the current SHS IV fund following its first closing.

With this fund, SHS is seeking to invest in further high growth companies in the life science sector.

www.shsvc.net

About Vimecon GmbH:

The medical technology company founded by Dr. Kai Markus became operative in 2008 with financing from the S-UBG Group in Aachen. It has developed a revolutionary laser-based catheter to treat atrial fibrillation, which indicates promising results as compared to drug treatment. The Vimecon catheters, which allow for pointed, linear and circular ablation, provide for much simpler treatment than currently available ablation catheters.

In 2012 the company opened an office in Houston, Texas. The proximity to the Texas Medical Center played a significant role here, as it is also located in Houston and has a successful history working with Vimecon. Vimecon has since intensified its collaboration with the physicians at the world's largest medical center.

www.vimecon.com

Further information:

Dr. Reinhard Saller
IRA WÜLFING KOMMUNIKATION GmbH
t: +49.(0)89. 2000 30-38
f: +49.(0)89. 2000 30-40
reinhard.saller@wuelfing-kommunikation.de